Method for the diagnosis and prognosis of cancer
Inventors
HAZNADAR, Majda • MATHE, Ewy • Patterson, Andrew D. • HARRIS, Curtis Craig • Gonzalez, Frank • KRAUSZ, Kristopher • Manna, Soumen
Assignees
Usa Heath And Human Services, Secretary of, Department of • US Department of Health and Human Services
Publication Number
US-10393745-B2
Publication Date
2019-08-27
Expiration Date
2034-07-11
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention provides methods and materials for diagnosing cancer in an individual using a tissue, blood or urine sample from the patient. Specifically, the disclosed method comprises determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, Cortisol sulfate and N-acetylneuraminic acid. The present invention also provides a method for determining the prognosis of a cancer patient by determining the level of one or more metabolite selected from the group consisting of creatine riboside, metabolite 561+, Cortisol sulfate and N-acetylneuraminic acid. Also provided are kits for detecting cancer or determining the prognosis of a cancer patient.
Core Innovation
The invention provides methods and materials for diagnosing cancer using tissue, blood, or urine samples from an individual by determining the level of one or more metabolites selected from creatine riboside, metabolite 561+, cortisol sulfate, and N-acetylneuraminic acid. The disclosed method also enables determining the prognosis of a cancer patient by measuring the levels of these specific metabolites. Kits for detecting cancer or determining prognosis are also provided.
The problem being addressed is the limitation of current early detection methods for lung cancer, which include spiral CT scanning that causes high false positive rates and exposes patients to radiation risk. There is a need for less expensive, safer, and more accurate methods to diagnose and predict cancer prognosis. Existing clinically accepted molecular biomarkers for lung cancer have limitations such as invasiveness and unavailability for early stage disease.
Claims Coverage
The patent contains multiple independent claims directed to methods of detecting creatine riboside and using this detection for diagnosing, identifying, monitoring treatment efficacy, and treating cancer. The inventive features focus on the detection methods, specific metabolites involved, and subsequent therapeutic actions.
Detection of creatine riboside by chromatography and mass spectrometry
A method for detecting creatine riboside in a sample from an individual by column chromatography and/or ionizing the sample to create creatine riboside ions with mass charge ratios of 264.1196+ or 90.0550+ followed by mass spectrometry detection.
Sample types used for creatine riboside detection
Using biological samples selected from blood, serum, plasma, or urine for detecting creatine riboside.
Detection of additional metabolites alongside creatine riboside
Simultaneous detection of at least one additional compound selected from metabolite 561+, cortisol sulfate, and N-acetylneuraminic acid during the creatine riboside assay.
High pressure liquid chromatography combined with quadrupole time-of-flight mass spectrometry
An assay employing HPLC, specifically using a C18 column, combined with quadrupole time-of-flight mass spectrometry for detecting creatine riboside and related metabolites.
Method of diagnosing and treating cancer based on creatine riboside detection
Obtaining a sample, detecting creatine riboside presence, diagnosing cancer if present, and subsequently administering effective cancer therapy.
Method for determining efficacy of cancer treatment by monitoring creatine riboside levels
Obtaining samples before and after treatment, determining creatine riboside levels using chromatography and mass spectrometry, and comparing these levels to assess treatment efficacy.
Method for identifying and treating individuals with cancer based on elevated creatine riboside
Detecting creatine riboside presence and level in a sample, identifying the individual as having cancer if levels are significantly higher than in non-cancer individuals, and administering anti-cancer therapy.
The independent claims cover the innovative method of detecting creatine riboside and related metabolites using chromatographic and mass spectrometry techniques in various biological samples. The claims extend to diagnosing cancer, monitoring treatment efficacy, and guiding therapeutic intervention based on measurable levels of creatine riboside and other specified metabolites.
Stated Advantages
The methods are less expensive, safe, and rapid compared to current screening methods like spiral CT scanning.
The biomarker-based method provides improved accuracy in early detection of cancer, including lung cancer and adenocarcinoma.
The use of non-invasive samples such as urine, blood plasma, and serum is advantageous for patient comfort and ease of sample collection.
The assays allow for monitoring treatment efficacy and predicting prognosis non-invasively.
Documented Applications
Diagnosis of cancer, particularly lung cancer, by detecting elevated levels of specific metabolites in samples such as tissue, blood, serum, plasma, or urine.
Determination of cancer prognosis by measuring biomarker levels indicative of survival times.
Monitoring efficacy of cancer treatments by comparing biomarker levels before and after therapy administration.
Use of kits comprising reagents and instructions to detect or quantify cancer-associated metabolites for clinical or research purposes.
Identification of individuals requiring cancer treatment based on biomarker detection results.
Interested in licensing this patent?